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Abstract
Background: A meta-analysis suggested the use of rosiglitazone was associated with an increased
risk for cardiovascular (CV) events. Rosiglitazone remained available for use as more definitive
safety trials were ongoing. This issue was reported in the lay media.
Objective: To review lay media articles to determine the extent of media coverage, the nature of
the messaging, and to assess the quality of reporting.
Methods: The Factiva media database was used to identify articles published between May 18 and
August 31, 2007. Two reviewers (a lay person and a physician) screened full text articles for
eligibility, appraised the articles for their tone (worrisome, neutral, not worrisome), and for the
quality of medical data reporting.
Results: The search identified 156 articles, 95 of which were eligible for our review. Agreement
between the lay and medical reviewers in the appraisal of the article tone was 67.4%. Among those
with agreement, the articles were often appraised as "worrisome" (75.3%). Among those with
disagreement, the lay reviewer was significantly more likely to appraise articles as worrisome
compared to the medical reviewer (77.4% vs. 3.2%, X2 = 9.11, P = 0.003). Cardiovascular risk was
discussed in 91.6% of the articles, but risk was often reported in qualitative or relative terms.
Conclusion: There were many lay media articles addressing the safety of rosiglitazone, and the
general messaging of these articles was considered "worrisome" by reviewers. Quality of risk
reporting in the articles reviewed was poor. The impact of such media coverage on public anxiety
and confidence in treatment should be explored.
Introduction
The lay media have become an important means for dis-
seminating health information [1-4]. It has been demon-
strated that media coverage related to medical therapy
significantly impacts how such therapies are perceived
and utilized [2]. However, it also been demonstrated that
there are clear deficiencies in the reporting of health
related stories in the media, and that less then half of med-
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ical therapy articles in the lay media report therapy related
risks in a satisfactory manner, and only a third have satis-
factory reporting of treatment benefits [5]. Given the
impact the lay media has on medical decision-making, it
is important to continually monitor the quality of the
medical news reporting.
In May of 2007, Nissen and colleagues published a sys-
tematic review and meta-analysis examining the effect of
rosiglitazone on cardiovascular outcomes, specifically it's
effect on risk for myocardial infarction and all cause mor-
tality [6]. This review pooled data from 42 studies and
provided data on 27 847 patients. While the overall event
rate for MI and death from any cause were low (158 events
in 26011 persons, and 61 events in 20445 persons respec-
tively), the authors did document a statistically significant
increase in the risk for MI among those using rosiglitazone
relative to those using a comparator agent (either another
oral hypoglycemic or placebo). There was also an increase
risk of death in the rosiglitazone group relative to the
comparator group, however this was not found to be sig-
nificant.
Diabetes and heart disease are highly prevalent conditions
and rosiglitazone was a medication that was increasingly
being used to treat diabetes and in theory, by reducing
insulin resistance, to reduce the risk of cardiovascular dis-
ease. Therefore, there was wide general interest surround-
ing the results of this meta-analysis. We conducted a
content analysis of lay media articles indexed in an inter-
national media database and specifically evaluated arti-
cles discussing rosiglitazone and sought to document the
extent of coverage and the quality of reporting. The objec-
tive of this study was to review the content of lay media
articles to determine how risk was communicated to the
public.
Methods
Search Strategy
The Factiva media database was used to identify poten-
tially eligible print media articles. Factiva is an interna-
tional database that provides access to print, television
and radio media from over 152 countries and uses a
unique system of subject headings. A search strategy was
developed in consultation with an academic librarian to
ensure capture of all potentially relevant articles. Factiva
indexing makes simple keyword searches most effective
and we identified all articles containing the keywords
"rosiglitazone" or "Avandia", published between May 18
and August 31, 2007. This search was restricted to English
language articles.
Inclusion and Exclusion Criteria
Two reviewers (DMR, GB) screened full text articles for eli-
gibility. Articles were eligible for inclusion if they dis-
cussed heart or cardiovascular disease OR safety, AND
rosiglitazone. Articles were excluded if they did not
address the safety of rosiglitazone, or if the article's pri-
mary focus was on the impact of the Nissen article on ros-
iglitazone's manufacturer's (GlaxoSmithKline) stock
prices.
Measures of Interest
Two reviewers (one lay reviewer [GB], one medical
reviewer [DMR]) appraised the articles for their tone. The
tone of the article was graded based on the degree of con-
text provided with the data reported on harm. Contextu-
alization of risk has been deemed an important aspect of
medical reporting [5]. The tone grade provided by the
reviewers does not reflect the actual data reported in the
original meta-analysis, but rather, how the data was pre-
sented in the media article. Tone was graded as worrisome
(risk of harm reported, potential benefits of treatment and
limitations of meta-analysis were not reported), neutral
(risk of harm reported, either potential benefits of treat-
ment and/or limitations of meta-analysis reported), or
not worrisome (risk of harm reported but focus of article
was benefits of treatment and limitations of meta-analy-
sis). The reporting of risk (relative, absolute or not speci-
fied) was documented. Other indicators of quality of data
reporting were also extracted. We employed a quality of
reporting checklist that was adapted from Cassels et al [5].
These indicators included the use of generic (rosiglita-
zone) and trade (Avandia™) names; reference to the class
of medication (thiazolideindiones or TZDs) or other
medications in the class (pioglitazone); whether the orig-
inal article was cited and whether sufficient information
was provided to locate the original articles (ie could a lay
reader conceivably find the original scientific article to
review); was expert opinion reported (experts could not
include the author) and if so, did experts disclose any
potential conflicts of interest; and were any additional
information resources provided. Data were extracted in
duplicate and agreement between the reviewers was deter-
mined.
Analysis
All extracted data were reported as proportions. Editorial
articles were analyzed separately from non-editorial arti-
cles on the measure of article and title tone. Overall agree-
ment between reviewers was caluculated using the Kappa
statistic. When applicable, differences in proportions were
tested using Chi square analysis.
Results
The search strategy yielded 159 original citations. Review
of these articles led to the exclusion of 64 articles (see fig-
ure 1) and 95 articles were included in our content analy-
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Tone of Articles
Editorial Articles
Six of the 95 eligible articles were editorials. There was
100% agreement between reviewers with respect to the
evaluation of tone in these editorials. The titles were con-
sidered "worrisome" in 3 of the 6 editorials, and "neutral"
in the remaining 3 articles. The content of the articles were
considered more negative, with 4 of the 6 articles being
graded as "worrisome", 1 being graded as "neutral" and 1
being graded as "not worrisome" (see Table 1).
Non-editorial Articles
Eighty-nine of the articles identified were non-editorial
articles. Agreement between the lay and medical reviewer
was quantified with a Kappa of only 0.579. Among the
articles with agreement, the titles and articles were most
often appraised as "worrisome" (58.4% and 75.3%
respectively) (see Table 1). Among those with disagree-
ment, the lay reviewer was significantly more likely to
appraise the titles (58.1% vs. 35.5%, X2 = 5.13, P = 0.02)
and articles (77.4% vs. 3.2%, X2 = 9.11, P = 0.003) as
"worrisome" compared to the medical reviewer.
Quality of Reporting
Data regarding the quality of reporting is detailed in Table
2. The concept of cardiovascular risk was explicitly
addressed in 91.6% of the articles (editorial and non-edi-
torial inclusive). Over half (58.6%) of the articles
expressed risk in numeric terms, the remainder (41.4%)
discussed it in qualitative terms. When risk was expressed
numerically, 98% of the articles reported relative risk, but
only 4.2% of the articles actually stated whether the risk
being reported was relative or absolute in nature. How-
ever, the reporting of relative risk was not significantly
associated with the appraisal of the article (X2 = 0.55, P =
0.97).
We found that all articles used both generic and trade
names. Reference to the class of TZD medications was
made in 69.5% of the articles and specific mention of the
other TZD medication, pioglitazone, was made in 57.9%
of the articles. Expert opinion was reported in only 13.7%
of articles, but whether this expert had any potential con-
flicts of interest was never reported. The original article by
Nissen et al. was explicitly mentioned in 73.7% of articles,
and among those referencing the article, sufficient infor-
mation to find the article for personal review was found in
87.1% of the articles. Additional sources of information
were seldom provided to the reader (12.6%), and the
most common resource provided to readers was the Amer-
ican Food and Drug Administration (FDA) website.
Discussion
This review shows that there was indeed wide coverage of
the meta-analysis by Nissen et al. [6] in the lay media. The
general messaging expressed in these articles was consid-
ered "worrisome", particularly by the lay reviewer, and the
overall quality of reporting was modest. These articles did
use generic and trade names when referring to rosiglita-
zone, and they frequently cited the original scientific arti-
cle. However, the reporting of risk was poor. Risk was
discussed qualitatively in 41.4% of the articles, and when
described in a quantitative manner, relative risks were
used. In our study, an article was classified as worrisome
if harm was discussed without placing the data of harm in
some context. As many readers of these lay media articles
will not read the original scientific article directly, the
media, holds considerable responsibility to produce bal-
anced reports on the quality of the original article, along
with presenting risk in both absolute and relative terms.
This review suggests that such appraisal was rarely done.
Perhaps the most interesting finding from our review is
that when disagreement in the appraisal of article tone
occurred, the lay reviewer consistently sensed more alarm
in the title/article than the medical reviewer. Even when
there is an attempt to provide data on both benefit and
harm, the lay reviewer was more likely to attend to the
message on harm. Given the prevalence of diabetes
around the world, the degree to which this media cover-
age provided patients with valuable information about
their treatment and the degree to which it caused height-
ened anxiety should be evaluated further.
While the results from the Nissen review raised concern,
rosiglitazone remained available for clinical use as clinical
practice leaders and drug regulators felt there were clear
limitations to the Nissen review, and that there was insuf-
ficient data to say that the drug should be withdrawn. The
meta-analysis included data from trials that were not
Study flow chart for article selection Figure 1
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Table 1: Categorization of overall tone (messaging) for the Editorial (n = 6) and non-Editorial articles (n = 89) identified
Type of Article Tone
Not Worrisome Neutral Worrisome
Editorial (n = 6)
Title 0 3 (50%) 3 (50%)
Article 1 (16.7%) 1 (16.7%) 4 (66.7%)
Non-Editorial (n = 89)
Title 13 (14.6%) 24 (27%) 52 (58.4%)
Article 9 (10.1%) 13 (14.6%) 67 (75.3%)
Table 2: Measures of quality of reporting
Quality Indicator Present n/N (%)
Reporting of Risk
Cardiovascular risk clearly reported? 87/95 (91.6)
Reported risk quantified? 51/87 (58.6)
Nature of risk (absolute vs. relative) clearly stated? 2/51 (4.2)*
Duality of Interest
Was an expert consulted? 13/95 (13.7)
If an expert was used, was there disclosure of potential conflict of interest? 0/13 (0)
Citation of Sources
Was the review by Nissen et al. cited? 70/95 (73.7)
Could the Nissen review be found based on information provided in the news report? 61/70 (87.1%)
Were additional information resources provided to readers? 12/95 (12.6)
Use of trade vs. generic drug names
Were both generic and trade names used in the report? 95/95 (100)
Was reference made to the class of medication (TZD)? 29/95 (30.5)
* All articles that did not specify the nature of risk reported, reported the cardiovascular risk in relative terms.Publish with BioMed Central    and   every 
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designed to examine cardiovascular safety, as such, these
trials did not have time-to-event data nor were all the car-
diovascular outcomes adjudicated. Nissen also excluded
trials with no cardiovascular events thereby introducing
some bias into the review.
Market reports indicate that the sales of rosiglitazone
dropped by $290 million in the United States in the
months that followed the publication of this paper [7]. It
would appear that irrespective of the quality of the scien-
tific data, public and professional confidence in this ther-
apy was compromised. A recent study by Shah et al.
similarly demonstrated that there was significant decrease
in new rosiglitazone prescriptions immediately following
the release of the Nissen review [8]. Given emerging evi-
dence on other adverse effects of TZDs such as osteoporo-
sis and heart failure [9,10], whether the decreased use of
rosiglitazone is entirely attributable to the media coverage
surrounding the Nissen review is not known. Further,
whether this change in practice was physician driven (due
to a re-evaluation of the evidence regarding relative bene-
fits and harms of rosiglitazone) or patient driven (possi-
bly related to concerns raised in the media) is unclear.
The lay media will continue to be an important knowl-
edge translation vehicle as it broadens communication of
new health information. However, this study highlights
that information on harm is perceived differently among
the medical and lay readers, and we suspect that these dif-
ferences in perceptions are in large part related the quality
of reporting. Ongoing quality assessments of medical
reporting are required to ensure that the messages com-
municated are truly informative to lay and medical audi-
ences alike.
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